Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

MIR135B inhibits CYLD. 2 / 2

| 2

➶

eidos

"Upregulated miR-135b targets the 3'UTR of CYLD , inhibits the expression of CYLD , and subsequently activates NF-kappaB and its downstream factors , which ultimately results in enhanced cell proliferation , migration , invasion , anti-apoptosis , and angiogenesis and confers aggressiveness of NSCLC ( Fig. 8G ) ."

33990540

➶

eidos

"MiR-135b targeted the 3'UTR of CYLD and inhibited CYLD expression , which further potentiated the activation of NF-kappaB signaling ."

33990540

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...